Elite Pharmaceuticals INC /NV/ 10-Q quarterly reports

Elite Pharmaceuticals announced its second-quarter 2026 financial results, showing a decrease in revenue but a significant swing to net income, driven by favorable changes in derivative instrument valuations.

Elite Pharmaceuticals announced a significant increase in revenue and net income for the six months ended September 30, 2025, driven by manufacturing fees and new product launches, alongside recent FDA approvals.

Elite Pharmaceuticals, Inc. reported a 114% surge in total revenue to $40.2 million for Q1 2025, driven by strong Elite label product sales and new launches, though a net loss of $5.9 million was recorded primarily due to a non-cash warrant valuation adjustment.

Elite Pharmaceuticals saw a revenue increase but also a larger net loss in the third quarter of fiscal year 2025, ended December 31, 2024.

Elite Pharmaceuticals saw a significant increase in revenue driven by its Elite-branded products, but also experienced a larger net loss due to changes in the fair value of derivative instruments and increased operating expenses.

Elite Pharmaceuticals saw a significant increase in revenue during the first quarter of fiscal year 2025, driven by strong sales of its Elite-branded products.

Elite Pharmaceuticals saw a significant increase in revenue during the third quarter of fiscal year 2024, driven by the launch of its own-label products.